Ontology type: schema:ScholarlyArticle
2016-04
AUTHORSBarbara Eichhorst, Michael Hallek
ABSTRACTDie chronisch-lymphatische Leukämie (CLL) ist die häufigste Leukämieform in der westlichen Welt und betrifft v. a. männliche sowie ältere Patienten. Trotz großer Fortschritte bei der Behandlung im fortgeschrittenen symptomatischen Stadium ist die Erkrankung nicht kurativ behandelbar. Die Therapie richtet sich nach der Fitness sowie Begleiterkrankungen und Vorhandensein einer Veränderung des TP53-Gens (Höchstrisiko-CLL). Für körperlich fitte Patienten ohne Höchstrisiko kommen intensivere Kombinationen aus Chemotherapie und CD20-Antikörper infrage, für ältere und/oder komorbide Patienten weniger intensive Therapien. Für Patienten mit Höchstrisiko-CLL sowie für die rezidivierte CLL stehen 2 orale Kinaseinhibitoren, die den Signaltransduktionsweg des B‑Zell-Rezeptors blockieren, zur Verfügung. Im Rezidiv kann alternativ nach an einer lang anhaltenden ersten Remission auch eine Chemoimmuntherapie wiederholt werden. Die allogene Stammzelltransplantation wird unter Abschätzung des Transplantationsrisikos v. a. bei Hochrisiko-CLL und nicht ausreichendem Ansprechen auf Kinaseinhibitoren erwogen. More... »
PAGES283-294
http://scigraph.springernature.com/pub.10.1007/s00761-016-0024-6
DOIhttp://dx.doi.org/10.1007/s00761-016-0024-6
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1032920258
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"author": [
{
"affiliation": {
"alternateName": "University of Cologne",
"id": "https://www.grid.ac/institutes/grid.6190.e",
"name": [
"Klinik I f\u00fcr Innere Medizin, Centrum f\u00fcr Integrierte Onkologie K\u00f6ln Bonn, Universit\u00e4t K\u00f6ln, Kerpener Str.\u00a062, 50924, K\u00f6ln, Deutschland"
],
"type": "Organization"
},
"familyName": "Eichhorst",
"givenName": "Barbara",
"id": "sg:person.01167624730.99",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167624730.99"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Cologne",
"id": "https://www.grid.ac/institutes/grid.6190.e",
"name": [
"Klinik I f\u00fcr Innere Medizin, Centrum f\u00fcr Integrierte Onkologie K\u00f6ln Bonn, Universit\u00e4t K\u00f6ln, Kerpener Str.\u00a062, 50924, K\u00f6ln, Deutschland"
],
"type": "Organization"
},
"familyName": "Hallek",
"givenName": "Michael",
"id": "sg:person.01025161256.58",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025161256.58"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1056/nejmoa1400376",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005487964"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2007-06-093906",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006649234"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2010-03-275420",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009414333"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2014-10-606038",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011356913"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1109016",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012874418"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1313984",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014014595"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(10)61381-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016656695"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2015.14",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018320802",
"https://doi.org/10.1038/leu.2015.14"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.39.2688",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022703461"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2014-07-586826",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023267831"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa075290",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024267663"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1315226",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032214328"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(13)70513-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034511288"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036959406"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3109/10428199609054782",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038473954"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(15)60027-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038838231"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.semcancer.2013.06.010",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042109829"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1215637",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047519052"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejm200012283432602",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051287807"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2012.216",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052508507",
"https://doi.org/10.1038/leu.2012.216"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2014-02-556399",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052522865"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074517562",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074517563",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074829732",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1083076559",
"type": "CreativeWork"
}
],
"datePublished": "2016-04",
"datePublishedReg": "2016-04-01",
"description": "Die chronisch-lymphatische Leuk\u00e4mie (CLL) ist die h\u00e4ufigste Leuk\u00e4mieform in der westlichen Welt und betrifft v. a. m\u00e4nnliche sowie \u00e4ltere Patienten. Trotz gro\u00dfer Fortschritte bei der Behandlung im fortgeschrittenen symptomatischen Stadium ist die Erkrankung nicht kurativ behandelbar. Die Therapie richtet sich nach der Fitness sowie Begleiterkrankungen und Vorhandensein einer Ver\u00e4nderung des TP53-Gens (H\u00f6chstrisiko-CLL). F\u00fcr k\u00f6rperlich fitte Patienten ohne H\u00f6chstrisiko kommen intensivere Kombinationen aus Chemotherapie und CD20-Antik\u00f6rper infrage, f\u00fcr \u00e4ltere und/oder komorbide Patienten weniger intensive Therapien. F\u00fcr Patienten mit H\u00f6chstrisiko-CLL sowie f\u00fcr die rezidivierte CLL stehen 2 orale Kinaseinhibitoren, die den Signaltransduktionsweg des B\u2011Zell-Rezeptors blockieren, zur Verf\u00fcgung. Im Rezidiv kann alternativ nach an einer lang anhaltenden ersten Remission auch eine Chemoimmuntherapie wiederholt werden. Die allogene Stammzelltransplantation wird unter Absch\u00e4tzung des Transplantationsrisikos v. a. bei Hochrisiko-CLL und nicht ausreichendem Ansprechen auf Kinaseinhibitoren erwogen.",
"genre": "research_article",
"id": "sg:pub.10.1007/s00761-016-0024-6",
"inLanguage": [
"de"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1119546",
"issn": [
"0947-8965",
"1433-0415"
],
"name": "Der Onkologe",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "22"
}
],
"name": "Neue Therapiekonzepte bei der chronisch-lymphatischen Leuk\u00e4mie",
"pagination": "283-294",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"9cd3ed334b52d078b5d59a4c4932496052984bbedf7ed84c001f1a2dd16ecd87"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00761-016-0024-6"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1032920258"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00761-016-0024-6",
"https://app.dimensions.ai/details/publication/pub.1032920258"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T15:55",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000533.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1007%2Fs00761-016-0024-6"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00761-016-0024-6'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00761-016-0024-6'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00761-016-0024-6'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00761-016-0024-6'
This table displays all metadata directly associated to this object as RDF triples.
133 TRIPLES
20 PREDICATES
50 URIs
19 LITERALS
7 BLANK NODES